Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $57.1M | $41.8M | $7.57M | $9.69M | $1.58M | $0.00 | $0.00 |
| Revenue growth | — | -26.7% | -81.9% | 27.9% | -83.7% | -100.0% | — |
| Operating income | -$1.23M | -$41.6M | -$97.5M | -$127M | -$184M | -$228M | -$156M |
| Operating margin | -2.2% | -99.6% | -1288.1% | -1313.4% | -11654.7% | — | — |
| Net income | -$631K | -$41.5M | -$97.3M | -$123M | -$161M | -$210M | -$149M |
| Net margin | -1.1% | -99.3% | -1284.5% | -1273.3% | -10211.1% | — | — |
| EPS (diluted) | -$4.22 | -$1.95 | -$2.71 | -$2.94 | -$2.75 | -$3.47 | -$2.43 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.75M | -$37.3M | -$75.4M | -$94.6M | -$116M | -$156M | -$128M |
| Capital expenditures | $964K | $1.53M | $1.95M | $1.76M | $921K | $3.85M | $374K |
| Free cash flow | -$3.71M | -$38.8M | -$77.4M | -$96.4M | -$117M | -$159M | -$129M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $85.8M | $50.9M | $51.7M | $33.7M | $63.2M | $71.2M | $45.4M |
| Total assets | $119M | $296M | $221M | $351M | $512M | $397M | $225M |
| Total liabilities | $9.08M | $12.5M | $22.2M | $37.3M | $38.6M | $92.9M | $44.0M |
| Long-term debt | — | — | $0.00 | $9.93M | $10.1M | $30.2M | $0.00 |
| Shareholders' equity | -$76.3M | $283M | $199M | $313M | $474M | $304M | $181M |
| Retained earnings | -$76.3M | -$118M | -$215M | -$338M | -$500M | -$710M | -$859M |
| Shares (wtd avg diluted) | 1.62M | 21.3M | 35.8M | 42.0M | 58.7M | 60.5M | 61.4M |
Every figure is extracted from PLIANT THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.